Biogen and AbbVie are withdrawing their multiple sclerosis (MS) drug Zinbryta (daclizumab) from global market after reports of eight cases of serious brain inflammation.The European Medicines Agency (EMA) has started an Article 20 referral procedure after reports of inflammatory encephalitis and meningoencephalitis.
Seven cases of serious inflammatory brain disorders including encephalitis and meningoencephalitis have been reported in Germany while the other case has come from Spain.
Read more: http://regulatoryaffairs.pharmaceutical-business-review.com/news/biogen-abbvie-pull-out-ms-drug-zinbryta-over-brain-inflammation-reports-050318-6071900